Neurotech startup Paradromics has made headlines by successfully implanting its brain-computer interface (BCI) in a human for the first time. This milestone took place at the University of Michigan, with the device being inserted and removed in a swift 20-minute procedure during epilepsy-related neurosurgery.
The Paradromics BCI strives to revolutionize communication for individuals with severe motor impairments, enabling them to use computer systems with brain signals alone. The company’s future clinical trials, set for later this year pending regulatory approval, aim to explore the technology’s long-term viability in humans.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
“We’re incredibly excited to move into the clinical stage,” said Matt Angle, founder and CEO of Paradromics. “This success is a testament to our commitment to enhancing BCI technologies.”
While Paradromics’ BCI awaits official clearance from the FDA, this achievement underscores a promising future for BCIs. The company has already demonstrated its skills in animal models, showcasing its ability to capture detailed brain activities at the neuronal level.
Paradromics joins the ranks of other pioneers such as Elon Musk’s Neuralink, Synchron, and Precision Neuroscience in driving forward the BCI space. With almost $100 million in funding and a strategic edge, Paradromics is on track to redefine neurotechnology.
